Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
June 28 — Senate Republicans and Democrats June 28 criticized a Medicare proposal intended to save money on drugs administered in doctors' offices and hospital outpatient departments.
Finance Committee Chairman Orrin Hatch (R-Utah) and ranking member Ron Wyden (D-Ore.) underscored the need to protect patients and small and rural providers as the committee held a hearing to examine a March proposed rule (81 Fed. Reg. 13,230; CMS-1670-P) aimed at reducing costs for Part B drugs.
“Protecting access is a big issue in rural areas where seniors today are often facing fewer choices and lower quality of care,” Wyden said. “And it’s extremely important that the project not result in patients being told that they have to go get treatment at the hospital, where treatment is typically more costly and less convenient.”
Patrick Conway, the CMS acting principal deputy administrator, defended the agency's rationale for the proposed model.
The Centers for Medicare & Medicaid Services proposed the model to help improve patient care and the value of Medicare drug spending, Conway said. The agency is analyzing comments and determining if any changes should be made, Conway told the committee.
The hearing represents the latest congressional backlash against the proposal. In April, all of the Republican members of the Finance Committee urged the CMS to scrap the model entirely, a move echoed by dozens of House Republicans in May (85 HCDR, 5/3/16). Some Democrats in Congress have called for changes to the proposed rule, but haven't gone as far as calling for its withdrawal (96 HCDR, 5/18/16).
Under the model, the CMS would test six approaches for paying for Part B drugs, such as cancer medications. In 2015, Medicare Part B spent $20 billion on outpatient drugs administered by physicians and hospital outpatient departments. In 2007, Medicare paid $11 billion for Part B drugs, and the average annual increase since then has been 8.6 percent, Conway said.
This significant growth has largely been driven by spending on drugs in the hospital outpatient setting, which more than doubled between 2007 and 2015, from $3 billion to $8 billion respectively, he told the committee.
However, Conway didn't present any new data at the hearing to show the proposed model would bring down drug costs, Ted Okon, the executive director of the Community Oncology Alliance, a group representing community oncology practices, told Bloomberg BNA June 28.
It is odd that the CMS came to Capitol Hill without offering any new data to defend its proposal, Okon said, adding that, to date, the agency hasn't presented any information about how the model would affect costs.
Even if the agency changes the rule, it will still disadvantage seniors, Okon said.
He said the agency should scrap the model and meet with drugmakers and providers to set up a reasonable approach that would truly look to solve quality and value issues.
Comments, which were due in May, showed that the Community Oncology Alliance and other oncology organizations want the CMS to pull the rule (91 HCDR, 5/11/16).
Before the comment deadline, Finance Committee Republicans and some of their House colleagues also asked that the agency withdraw the rule (85 HCDR, 5/3/16).
The proposed experiment would require providers in the vast majority of the country to participate in a least one dramatic payment change, Finance Committee Republicans told the CMS in their April letter.
However, some have asked why the CMS proposed “such a large, expansive demonstration,” Sen. Tom Carper (D-Del.) said at the hearing.
The model is a proposal, and the CMS sought comments about its scope and is analyzing that feedback, Conway said. Part of the reason why the CMS proposed such an expansive pilot project is because the agency will need enough data to evaluate the model's results once it is live, he told committee members.
To contact the reporter on this story: Michael D. Williamson in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Brian Broderick at email@example.com
Details about the hearing are at http://www.finance.senate.gov/hearings/examining-the-proposed-medicare-part-b-drug-demonstration.
The proposed rule is at https://www.gpo.gov/fdsys/pkg/FR-2016-03-11/html/2016-05459.htm.
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)